Rolling Green Cannabis

Rolling Green Cannabis concentrated 83.27% of August 2026 sales in Flower while Pre-Roll held 16.73%, with Flower down 36.22% year over year and 2.69% month over month, and Pre-Roll down 26.54% year over year and 6.60% month over month; the brand’s overall sales decline of 34.79% year over year and a modest 1.51% average price increase indicate mix-driven pressure more than pricing-driven attrition. Within New York Flower, the brand sat at rank 5, a position that contrasts with the steeper Flower contraction vs. Pre-Roll and implies that August 2026 performance was primarily constrained by core-category volume erosion rather than competitive displacement across the portfolio. The thesis is that an over-weight in a shrinking core (Flower) amplified the year-over-year contraction, while limited exposure to the relatively less negative Pre-Roll trajectory reduced the portfolio’s ability to cushion declines.

Average Flower price at $59.13 versus Pre-Roll at $13.36, alongside a 2.69% month-over-month drop in Flower and a 6.60% decline in Pre-Roll, suggests price architecture is not the immediate lever, whereas rank 5 in New York Flower points to maintained relevance within the segment despite a 36.22% year-over-year contraction. The 16.73% share in Pre-Roll, paired with a 26.54% year-over-year decline and steeper month-over-month dip than Flower, indicates that smaller, faster-softening adjacencies are not yet offsetting core-category cyclicality. The thesis is that stabilizing Flower velocity while selectively expanding Pre-Roll share could rebalance risk without broad price moves, positioning Rolling Green Cannabis to protect rank in Flower while building a secondary volume lane that dampens volatility.